Impact of Tacrolimus Intra-patient Variability in Adverse Outcomes After Organ Transplantation

Overview

Journal World J Transplant

Publisher Baishideng Publishing Group

Specialty General Surgery

Date 2023 Sep 25

PMID 37746041

Authors

Maria Clara Morais

Maria Eduarda Soares

Gabriela Costa

Laura Guerra

Nayana Vaz

Liana Codes

Paulo Lisboa Bittencourt

Affiliations

Soon will be listed here.

Abstract

Tacrolimus (Tac) is currently the most common calcineurin-inhibitor employed in solid organ transplantation. High intra-patient variability (IPV) of Tac (Tac IPV) has been associated with an increased risk of immune-mediated rejection and poor outcomes after kidney transplantation. Few data are available concerning the impact of high Tac IPV in non-kidney transplants. However, even in kidney transplantation, there is still a controversy whether high Tac IPV is indeed detrimental in respect to graft and/or patient survival. This may be due to different methods employed to evaluate IPV and distinct time frames adopted to assess graft and patient survival in those reports published up to now in the literature. Little is also known about the influence of high Tac IPV in the development of other untoward adverse events, update of the current knowledge regarding the impact of Tac IPV in different outcomes following kidney, liver, heart, lung, and pancreas tran splantation to better evaluate its use in clinical practice.

References

Leino A, King E, Jiang W, Vinks A, Klawitter J, Christians U . Assessment of tacrolimus intrapatient variability in stable adherent transplant recipients: Establishing baseline values. Am J Transplant. 2018; 19(5):1410-1420. DOI: 10.1111/ajt.15199. View

Gold A, Tonshoff B, Dohler B, Susal C . Association of graft survival with tacrolimus exposure and late intra-patient tacrolimus variability in pediatric and young adult renal transplant recipients-an international CTS registry analysis. Transpl Int. 2020; 33(12):1681-1692. DOI: 10.1111/tri.13726. View

Coste G, Lemaitre F . The Role of Intra-Patient Variability of Tacrolimus Drug Concentrations in Solid Organ Transplantation: A Focus on Liver, Heart, Lung and Pancreas. Pharmaceutics. 2022; 14(2). PMC: 8878862. DOI: 10.3390/pharmaceutics14020379. View

Kuypers D . Intrapatient Variability of Tacrolimus Exposure in Solid Organ Transplantation: A Novel Marker for Clinical Outcome. Clin Pharmacol Ther. 2019; 107(2):347-358. DOI: 10.1002/cpt.1618. View

ORegan J, Canney M, Connaughton D, OKelly P, Williams Y, Collier G . Tacrolimus trough-level variability predicts long-term allograft survival following kidney transplantation. J Nephrol. 2015; 29(2):269-276. DOI: 10.1007/s40620-015-0230-0. View

Kostalova B, Mala-Ladova K, Dusilova Sulkova S, Denhaerynck K, de Geest S, Maly J . Comparison of different methods to assess tacrolimus concentration intra-patient variability as potential marker of medication non-adherence. Front Pharmacol. 2022; 13:973564. PMC: 9609782. DOI: 10.3389/fphar.2022.973564. View

Marco D, Salas M, Gutierrez-Garcia G, Monge I, Riu G, Carcelero E . Impact of Early Intrapatient Variability of Tacrolimus Concentrations on the Risk of Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide. Pharmaceuticals (Basel). 2022; 15(12). PMC: 9784628. DOI: 10.3390/ph15121529. View

Schumacher L, Leino A, Park J . Tacrolimus intrapatient variability in solid organ transplantation: A multiorgan perspective. Pharmacotherapy. 2020; 41(1):103-118. DOI: 10.1002/phar.2480. View

Dopazo C, Bilbao I, Garcia S, Gomez-Gavara C, Caralt M, Campos-Varela I . High intrapatient variability of tacrolimus exposure associated with poorer outcomes in liver transplantation. Clin Transl Sci. 2022; 15(6):1544-1555. PMC: 9199878. DOI: 10.1111/cts.13276. View

10.

Taber D, Su Z, Fleming J, McGillicuddy J, Posadas-Salas M, Treiber F . Tacrolimus Trough Concentration Variability and Disparities in African American Kidney Transplantation. Transplantation. 2017; 101(12):2931-2938. PMC: 5709143. DOI: 10.1097/TP.0000000000001840. View

11.

Campagne O, Mager D, Tornatore K . Population Pharmacokinetics of Tacrolimus in Transplant Recipients: What Did We Learn About Sources of Interindividual Variabilities?. J Clin Pharmacol. 2018; 59(3):309-325. PMC: 7395655. DOI: 10.1002/jcph.1325. View

12.

Stefanovic N, Velickovic-Radovanovic R, Dankovic K, Pavlovic I, Catic-dordevic A, Basic J . Effect of the Interrelation between CYP3A5 Genotype, Concentration/Dose Ratio and Intrapatient Variability of Tacrolimus on Kidney Graft Function: Monte Carlo Simulation Approach. Pharmaceutics. 2021; 13(11). PMC: 8622919. DOI: 10.3390/pharmaceutics13111970. View

13.

Gallagher H, Sarwar G, Tse T, Sladden T, Hii E, Yerkovich S . Erratic tacrolimus exposure, assessed using the standard deviation of trough blood levels, predicts chronic lung allograft dysfunction and survival. J Heart Lung Transplant. 2015; 34(11):1442-8. DOI: 10.1016/j.healun.2015.05.028. View

14.

Sablik K, Clahsen-van Groningen M, Hesselink D, van Gelder T, Betjes M . Tacrolimus intra-patient variability is not associated with chronic active antibody mediated rejection. PLoS One. 2018; 13(5):e0196552. PMC: 5944964. DOI: 10.1371/journal.pone.0196552. View

15.

Shuker N, van Gelder T, Hesselink D . Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management. Transplant Rev (Orlando). 2015; 29(2):78-84. DOI: 10.1016/j.trre.2015.01.002. View

16.

Goodall D, Willicombe M, McLean A, Taube D . High Intrapatient Variability of Tacrolimus Levels and Outpatient Clinic Nonattendance Are Associated With Inferior Outcomes in Renal Transplant Patients. Transplant Direct. 2017; 3(8):e192. PMC: 5540630. DOI: 10.1097/TXD.0000000000000710. View

17.

Katada Y, Nakagawa S, Itohara K, Suzuki T, Kato R, Endo H . Association between time in therapeutic range of tacrolimus blood concentration and acute rejection within the first three months after lung transplantation. J Pharm Health Care Sci. 2022; 8(1):25. PMC: 9526258. DOI: 10.1186/s40780-022-00256-9. View

18.

Rahamimov R, Tifti-Orbach H, Zingerman B, Green H, Schneider S, Chagnac A . Reduction of exposure to tacrolimus trough level variability is associated with better graft survival after kidney transplantation. Eur J Clin Pharmacol. 2019; 75(7):951-958. DOI: 10.1007/s00228-019-02643-y. View

19.

Nuchjumroon A, Vadcharavivad S, Singhan W, Poosoonthornsri M, Chancharoenthana W, Udomkarnjananun S . Comparison of Tacrolimus Intra-Patient Variability during 6-12 Months after Kidney Transplantation between CYP3A5 Expressers and Nonexpressers. J Clin Med. 2022; 11(21). PMC: 9658797. DOI: 10.3390/jcm11216320. View

20.

Rayar M, Tron C, Jezequel C, Beaurepaire J, Petitcollin A, Houssel-Debry P . High Intrapatient Variability of Tacrolimus Exposure in the Early Period After Liver Transplantation Is Associated With Poorer Outcomes. Transplantation. 2018; 102(3):e108-e114. DOI: 10.1097/TP.0000000000002052. View